loading
Precedente Chiudi:
$5.61
Aprire:
$5.67
Volume 24 ore:
542.99K
Relative Volume:
0.43
Capitalizzazione di mercato:
$775.92M
Reddito:
$62.04M
Utile/perdita netta:
$-533.34M
Rapporto P/E:
-1.4719
EPS:
-3.92
Flusso di cassa netto:
$-473.07M
1 W Prestazione:
+3.18%
1M Prestazione:
-16.32%
6M Prestazione:
-23.80%
1 anno Prestazione:
-28.41%
Intervallo 1D:
Value
$5.555
$5.82
Intervallo di 1 settimana:
Value
$5.315
$5.86
Portata 52W:
Value
$4.95
$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name
Nome
Vir Biotechnology Inc
Name
Telefono
415-906-4324
Name
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Name
Dipendente
408
Name
Cinguettio
@Vir_Biotech
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
VIR's Discussions on Twitter

Confronta VIR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VIR
Vir Biotechnology Inc
5.775 775.92M 62.04M -533.34M -473.07M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.30 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
582.72 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.94 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.12 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
253.22 26.16B 3.81B -644.79M -669.77M -6.24

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-01-29 Downgrade JP Morgan Overweight → Neutral
2023-09-08 Downgrade BofA Securities Buy → Neutral
2023-03-06 Aggiornamento JP Morgan Neutral → Overweight
2023-02-21 Aggiornamento Goldman Neutral → Buy
2023-01-27 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-09-14 Iniziato SVB Leerink Outperform
2022-09-09 Iniziato Morgan Stanley Underweight
2022-03-03 Aggiornamento Robert W. Baird Underperform → Neutral
2021-12-21 Downgrade Robert W. Baird Neutral → Underperform
2021-10-25 Aggiornamento JP Morgan Underweight → Neutral
2021-09-22 Downgrade Goldman Buy → Neutral
2021-06-04 Ripresa Robert W. Baird Neutral
2021-01-27 Downgrade JP Morgan Neutral → Underweight
2021-01-20 Reiterato H.C. Wainwright Buy
2020-10-05 Iniziato BofA Securities Buy
2020-09-14 Aggiornamento Goldman Neutral → Buy
2020-09-11 Aggiornamento JP Morgan Underweight → Neutral
2020-08-20 Iniziato Needham Buy
2020-03-19 Downgrade JP Morgan Neutral → Underweight
2020-03-13 Downgrade Goldman Buy → Neutral
2020-02-27 Downgrade Robert W. Baird Neutral → Underperform
2020-02-04 Downgrade JP Morgan Overweight → Neutral
2019-11-14 Iniziato Robert W. Baird Neutral
2019-11-05 Iniziato Barclays Overweight
2019-11-05 Iniziato Cowen Outperform
2019-11-05 Iniziato Goldman Buy
2019-11-05 Iniziato JP Morgan Overweight
Mostra tutto

Vir Biotechnology Inc Borsa (VIR) Ultime notizie

pulisher
Apr 19, 2025

When (VIR) Moves Investors should Listen - news.stocktradersdaily.com

Apr 19, 2025
pulisher
Apr 17, 2025

5 Analysts Have This To Say About Vir Biotechnology - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq

Apr 16, 2025
pulisher
Apr 09, 2025

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Insider Monkey

Apr 09, 2025
pulisher
Apr 08, 2025

10 Stocks Under $10 that Will Triple - Insider Monkey

Apr 08, 2025
pulisher
Apr 05, 2025

Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock By Investing.com - Investing.com South Africa

Apr 05, 2025
pulisher
Apr 04, 2025

Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Vir Biotechnology CEO Sells Shares to Cover Tax Obligations - TradingView

Apr 04, 2025
pulisher
Apr 03, 2025

Vir Biotechnology stock hits 52-week low at $6.07 By Investing.com - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Vir Biotechnology stock hits 52-week low at $6.07 - Investing.com

Apr 03, 2025
pulisher
Apr 01, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution - simplywall.st

Mar 31, 2025
pulisher
Mar 28, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo

Mar 28, 2025
pulisher
Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India

Mar 26, 2025
pulisher
Mar 24, 2025

(VIR) Trading Advice - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 21, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow

Mar 21, 2025
pulisher
Mar 20, 2025

Hepatitis D Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com

Mar 20, 2025
pulisher
Mar 13, 2025

(VIR) Trading Signals - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 13, 2025

Morgan Stanley maintains $20 target on Vir Biotechnology stock By Investing.com - Investing.com Canada

Mar 13, 2025
pulisher
Mar 13, 2025

Morgan Stanley maintains $20 target on Vir Biotechnology stock - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial -March 13, 2025 at 08:30 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire

Mar 13, 2025
pulisher
Mar 11, 2025

Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus

Mar 11, 2025
pulisher
Mar 11, 2025

SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $35.67 - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Principal Financial Group Inc. Has $3.28 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha

Mar 04, 2025
pulisher
Mar 03, 2025

Vir Biotechnology's (VIR) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Mar 03, 2025
pulisher
Mar 03, 2025

What is HC Wainwright’s Forecast for VIR Q1 Earnings? - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

(VIR) On The My Stocks Page - Stock Traders Daily

Mar 02, 2025
pulisher
Mar 02, 2025

HC Wainwright Reaffirms “Buy” Rating for Vir Biotechnology (NASDAQ:VIR) - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating - TipRanks

Mar 02, 2025
pulisher
Mar 02, 2025

Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, Barclays Analyst Says - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Canada Finance

Mar 01, 2025
pulisher
Feb 28, 2025

7 Analysts Have This To Say About Vir Biotechnology - Benzinga

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding Vir Biotechnology Inc (VIR): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

Vir Biotechnology’s Transformative Year: Earnings Call Insights - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology Becomes Oversold (VIR) - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

Vir Biotechnology Inc Azioni (VIR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Capitalizzazione:     |  Volume (24 ore):